About this Research Topic
The JAK-STAT signaling pathway is crucial for human immune response to environmental cues and a range of growth factors and cytokines, with downstream cellular effects such as the development, differentiation, and function of immune cells. Aberrant JAK/STAT transduction activates proinflammatory cytokine signaling that jeopardizes immune homeostasis and thus contributes to the development of autoimmune diseases. Activation of IFNa/b -STAT1/2 pathway is implicated in COVID-19 infection and cytokine storm, and abnormal STAT1/2/4 or TYK2 signaling is identified in autoimmune diseases such as lupus. The triggering of post-COVID disease and autoimmune conditions by viral infections has been of recent interest to the scientific community.
The success of several small-molecule JAK inhibitors in the treatment of autoimmune disease and COVID-19 disease demonstrates that targeting the JAK/STAT pathway is efficient in suppressing a hyperimmune response and sheds light on their therapeutic potential in several autoimmune diseases and post-COVID disease.
Viral infections are one of the environmental triggers that can lead to various post-infection diseases including autoimmunity. There are a growing number of case reports of various autoimmune diseases as well as lung fibrosis occurring after COVID-19, yet there is no large-scale population-based evidence to support this potential association, the underlying mechanism, and potential treatments. This Research Topic aims to provide closer insight into the association between the JAK/STAT signaling pathway, post-COVID-19 disease, including autoimmune diseases, and potential treatment using JAK inhibitors. We want to discuss the signal transduction and molecular mechanism involving immune function through the JAK-STAT pathway, outline the role of this pathway in post-COVID disease including autoimmune disease, and explain the clinical trial evidence for the therapeutic potential of targeting the JAK-STAT signaling pathway.
We welcome the submission of Original Research, Review/Mini-Review, and Clinical Trial articles covering, but not limited to, the following research areas:
• JAK/STAT signaling modulation associated with post COVID-19 disease including autoimmune diseases
• Critical roles of STATs in gene regulation signatures across regulatory mechanism in post COVID-19 diseases and autoimmune diseases
• New data shedding light on genetic signatures affecting the regulation mediated by JAK/STAT signaling
• New therapeutic agents for counterbalancing active JAK/STAT pathway in diseases
• Research that emphasizes functions of JAK inhibitors as a treatment
Original Research articles that contain novel and prominent information of general interest to researchers in these fields are highly appreciated.
The success of several small-molecule JAK inhibitors in the treatment of autoimmune disease and COVID-19 disease demonstrates that targeting the JAK/STAT pathway is efficient in suppressing a hyperimmune response and sheds light on their therapeutic potential in several autoimmune diseases and post-COVID disease.
Viral infections are one of the environmental triggers that can lead to various post-infection diseases including autoimmunity. There are a growing number of case reports of various autoimmune diseases as well as lung fibrosis occurring after COVID-19, yet there is no large-scale population-based evidence to support this potential association, the underlying mechanism, and potential treatments. This Research Topic aims to provide closer insight into the association between the JAK/STAT signaling pathway, post-COVID-19 disease, including autoimmune diseases, and potential treatment using JAK inhibitors. We want to discuss the signal transduction and molecular mechanism involving immune function through the JAK-STAT pathway, outline the role of this pathway in post-COVID disease including autoimmune disease, and explain the clinical trial evidence for the therapeutic potential of targeting the JAK-STAT signaling pathway.
We welcome the submission of Original Research, Review/Mini-Review, and Clinical Trial articles covering, but not limited to, the following research areas:
• JAK/STAT signaling modulation associated with post COVID-19 disease including autoimmune diseases
• Critical roles of STATs in gene regulation signatures across regulatory mechanism in post COVID-19 diseases and autoimmune diseases
• New data shedding light on genetic signatures affecting the regulation mediated by JAK/STAT signaling
• New therapeutic agents for counterbalancing active JAK/STAT pathway in diseases
• Research that emphasizes functions of JAK inhibitors as a treatment
Original Research articles that contain novel and prominent information of general interest to researchers in these fields are highly appreciated.
Keywords: JAK/STAT pathway, post COVID-19 disease, autoimmune disease, previous COVID-19 infection, cytokines, JAK inhibitors, lupus
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
